Docking for Molecules That Bind in a Symmetric Stack with SymDOCK

Abstract

Discovering ligands for amyloid fibrils, such as those formed by the tau protein, is an area of great current interest. In recent structures, ligands bind in stacks in the tau fibrils to reflect the rotational and translational symmetry of the fibril itself; in these structures, the ligands make few interactions with the protein but interact extensively with each other. To exploit this symmetry and stacking, we developed SymDOCK, a method to dock molecules that follow the protein's symmetry. For each prospective ligand pose, we apply the symmetry operation of the fibril to generate a self-interacting and fibril-interacting stack, checking that doing so will not cause a clash between the original molecule and its image. Absent a clash, we retain that pose and add the ligand−ligand van der Waals energy to the ligand's docking score (here using DOCK3.8). We can check these geometries and energies using an implementation of ANI, a neural-network-based quantum-mechanical evaluation of the ligand stacking energies. In retrospective calculations, symmetry docking can reproduce the poses of three tau PET tracers whose structures have been determined. More convincingly, in a prospective study, SymDOCK predicted the structure of the PET tracer MK-6240 bound in a symmetrical stack to AD PHF tau before that structure was determined; the docked pose was used to determine how MK-6240 fit the cryo-EM density. In proof-of-concept studies, SymDOCK enriched known ligands over property-matched decoys in retrospective screens without sacrificing docking speed and can address large library screens that seek new symmetrical stackers. Future applications of this approach will be considered.

Cryo-EM Structures Reveal Tau Filaments from Down Syndrome Adopt Alzheimer’s Disease Fold

“…For example, we expect that the cleft of the PHF fold in DS bears an identical pocket for stacked small-molecule binding, as we have demonstrated with the positron emission tomography ligand GTP1 [70] and as Kunach et al demonstrated with the positron emission tomography ligand MK-6240 [71] in tau PHFs from sAD. Based on this novel binding mode, new in silico docking methods [72] may predict small molecules with superior properties for development as nextgeneration diagnostic ligands or therapeutic inhibitors targeting the tau fold in DS and AD.…”

Cryo-EM structures reveal tau filaments from Down syndrome adopt Alzheimer’s disease fold

“…For example, we expect that the cleft of the PHF fold in DS bears an identical pocket for stacked small-molecule binding, as we have demonstrated with the positron emission tomography ligand GTP1 [ 70 ] and as Kunach et al demonstrated with the positron emission tomography ligand MK-6240 [ 71 ] in tau PHFs from sAD. Based on this novel binding mode, new in silico docking methods [ 72 ] may predict small molecules with superior properties for development as next-generation diagnostic ligands or therapeutic inhibitors targeting the tau fold in DS and AD.…”